Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae
- PMID: 31789374
- DOI: 10.1093/jac/dkz501
Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae
Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) are classified as carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE; the majority of CPE in Japan produce IMP carbapenemase.
Objectives: We evaluated the clinico-epidemiological and microbiological information and effects of IMP-type carbapenemase production in CRE.
Methods: Patients with isolations of CRE (MICs of meropenem ≥2 mg/L, imipenem ≥2 mg/L or cefmetazole ≥64 mg/L) from August 2016 to March 2018 were included. Microbiological analyses and WGS were conducted and clinical parameters were compared between groups. Independent predictors for the isolation of CPE from patients were identified by logistic regression. For comparing clinical outcomes, a stabilized inverse probability weighting method was used to conduct propensity score-adjusted analysis.
Results: Ninety isolates (27 CPE and 63 non-CPE) were collected from 88 patients (25 CPE and 63 non-CPE). All CPE tested positive for IMP carbapenemase. Antibiotic resistance (and the presence of resistance genes) was more frequent in the CPE group than in the non-CPE group. Independent predictors for CPE isolation were residence in a nursing home or long-term care facility, longer prior length of hospital stay (LOS), use of a urinary catheter and/or nasogastric tube, dependent functional status and exposure to carbapenem. Although in-hospital and 30 day mortality rates were similar between the two groups, LOS after CRE isolation was longer in the CPE group.
Conclusions: IMP-CPE were associated with prolonged hospital stays and had different clinical and microbiological characteristics compared with non-CPE. Tailored approaches are necessary for the investigational and public health reporting, and clinical and infection prevention perspectives for IMP-CPE and non-CPE.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan.Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01483-20. doi: 10.1128/AAC.01483-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33257451 Free PMC article.
-
Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.Clin Microbiol Infect. 2023 May;29(5):629-634. doi: 10.1016/j.cmi.2023.01.005. Epub 2023 Jan 12. Clin Microbiol Infect. 2023. PMID: 36641053
-
Trends and molecular characteristics of carbapenemase-producing Enterobacteriaceae in Japanese hospital from 2006 to 2015.J Infect Chemother. 2020 Jul;26(7):667-671. doi: 10.1016/j.jiac.2020.02.002. Epub 2020 Mar 26. J Infect Chemother. 2020. PMID: 32222331
-
Clinical characteristics and treatment of IMP-type carbapenemase-producing Enterobacteriaceae bacteremia: Case series and literature review.J Infect Chemother. 2023 Jan;29(1):26-32. doi: 10.1016/j.jiac.2022.09.003. Epub 2022 Sep 12. J Infect Chemother. 2023. PMID: 36100144 Review.
-
Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE).Expert Rev Anti Infect Ther. 2016;14(1):95-108. doi: 10.1586/14787210.2016.1106940. Epub 2015 Nov 4. Expert Rev Anti Infect Ther. 2016. PMID: 26535959 Review.
Cited by
-
The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance.BMC Infect Dis. 2024 Feb 15;24(1):209. doi: 10.1186/s12879-024-09107-4. BMC Infect Dis. 2024. PMID: 38360618 Free PMC article.
-
A critical role of outer membrane vesicles in antibiotic resistance in carbapenem-resistant Klebsiella pneumoniae.Ann Clin Microbiol Antimicrob. 2023 Nov 2;22(1):95. doi: 10.1186/s12941-023-00645-4. Ann Clin Microbiol Antimicrob. 2023. PMID: 37919721 Free PMC article.
-
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol. 2022 Mar 15;12:823684. doi: 10.3389/fcimb.2022.823684. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372099 Free PMC article. Review.
-
Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-Resistant Escherichia coli Harboring blaNDM-1 and blaNDM-5.Antibiotics (Basel). 2021 Aug 23;10(8):1023. doi: 10.3390/antibiotics10081023. Antibiotics (Basel). 2021. PMID: 34439073 Free PMC article.
-
Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review.Front Cell Infect Microbiol. 2021 Apr 23;11:601968. doi: 10.3389/fcimb.2021.601968. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 33968793 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
